NCT05279638

Brief Summary

it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2022

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

February 23, 2022

Completed
20 days until next milestone

First Posted

Study publicly available on registry

March 15, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2023

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

March 15, 2022

Status Verified

March 1, 2022

Enrollment Period

1 year

First QC Date

February 23, 2022

Last Update Submit

March 6, 2022

Conditions

Psoriasis VulgarisAutophagy

Keywords

serum markerATG5

Outcome Measures

Primary Outcomes (1)

  • serum level of ATG5 in psoriatic patients

    evaluation of serum ATG5 in psoriasis vulgaris patients by ELISA

    Within 6 months

Study Arms (2)

psoriasis vulgaris patients

psoriasis vulgaris patients , both sex , 18,55 years old

Diagnostic Test: serum ATG5

healthy participants

Diagnostic Test: serum ATG5

Interventions

serum ATG5DIAGNOSTIC_TEST

This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid

Also known as: human autophgy protien 5 ELISA kit
healthy participantspsoriasis vulgaris patients

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Patients with psoriasis vulgaris and healthy participatins

You may qualify if:

  • Psoriasis vulgaris of both sex, age 18-55 years

You may not qualify if:

  • i. Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University

Sohag, Egypt

RECRUITING

Central Study Contacts

Ayatallah Hamdi Abdelrahmim

CONTACT

01005482447ayatallah_hamdy_post@med.sohag.edu.eg

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident physician

Study Record Dates

First Submitted

February 23, 2022

First Posted

March 15, 2022

Study Start

February 1, 2022

Primary Completion

February 1, 2023

Study Completion

January 1, 2024

Last Updated

March 15, 2022

Record last verified: 2022-03

Locations

EG(1)